Xu Zhengquan, Ding Yanhong, Lu Wei, Zhang Ke, Wang Fei, Ding Guanxiong, Wang Jianqing
Department of Orthopedics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Nanjing, China.
Department of Urology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Nanjing, China.
PeerJ. 2021 Mar 31;9:e11133. doi: 10.7717/peerj.11133. eCollection 2021.
Metastatic castration-resistant prostate cancer (mCRPC) is the lethal stage and the leading cause of death in prostate cancer patients, among which bone metastasis is the most common site. Here in this article, we downloaded the gene expression data and clinical information from online dataset. We found that prostate cancer metastasis in bone is prone to have higher prostate-specific antigen (PSA) and longer time on first-line androgen receptor signaling inhibitors (ARSI). A total of 1,263 differentially expressed genes (DEGs) were identified and results of functional enrichment analysis indicated the enrichment in categories related to cell migration, cancer related pathways and metabolism. We identified the top 20 hub genes from the PPI network and analyzed the clinical characteristics correlated with these hub genes. Finally, we analyzed the immune cell abundance ratio of each sample in different groups. Our results reveal the different clinical characteristics, the immune cell infiltration pattern in different sites of mCRPC, and identify multiple critical related genes and pathways, which provides basis for individualized treatment.
转移性去势抵抗性前列腺癌（mCRPC）是前列腺癌患者的致死阶段和主要死因，其中骨转移是最常见的部位。在本文中，我们从在线数据集下载了基因表达数据和临床信息。我们发现前列腺癌骨转移易于出现较高的前列腺特异性抗原（PSA）以及更长时间使用一线雄激素受体信号抑制剂（ARSI）。共鉴定出1263个差异表达基因（DEG），功能富集分析结果表明其在与细胞迁移、癌症相关通路和代谢相关的类别中富集。我们从蛋白质-蛋白质相互作用（PPI）网络中鉴定出前20个枢纽基因，并分析了与这些枢纽基因相关的临床特征。最后，我们分析了不同组中每个样本的免疫细胞丰度比率。我们的结果揭示了mCRPC不同部位的不同临床特征、免疫细胞浸润模式，并鉴定出多个关键相关基因和通路，为个体化治疗提供了依据。
